The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.38 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Jazz Pharmaceuticals's Beneish M-Score or its related term are showing as below:
JAZZ'
s Beneish M-Score Range Over the Past 10 Years
Min: -3 Med: -2.65 Max: -2.29
Current: -2.38
During the past 13 years, the highest Beneish M-Score of Jazz Pharmaceuticals was -2.29. The lowest was -3.00. And the median was -2.65.
Jazz Pharmaceuticals Beneish M-Score Related Terms
Jazz Pharmaceuticals Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JAZZ vs ASND, SMMT, BBIO: Beneish M-Score Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Jazz Pharmaceuticals for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.1728
+
0.528 * 1.0092
+
0.404 * 0.9508
+
0.892 * 1.092
+
0.115 * 1.0137
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.9752
+
4.679 * -0.030099
-
0.327 * 0.9756
=
-2.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(661.484 / (661.484 + 228.05))
/
(712.897 / (712.897 + 258.9))
=
0.74363
/
0.733586
=
1.0137
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(29.493 - -947.717
-
1334.173)
/
11859.6
=
-0.030099
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Jazz Pharmaceuticals has a M-score of -2.38 suggests that the company is unlikely to be a manipulator.
Jazz Pharmaceuticals (JAZZ) has a Beneish M-Score of -2.38 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Jazz Pharmaceuticals and its competitors. According to the industry distribution chart, Jazz Pharmaceuticals ranks #411 out of 831 companies in the Biotechnology industry, placing it in the top 49.5%.
Is Jazz Pharmaceuticals' Beneish M-Score too high?
Jazz Pharmaceuticals' current Beneish M-Score is -2.38. Based on the distribution chart, Jazz Pharmaceuticals ranks #411 out of 831 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Beneish M-Score compare to ASND and SMMT?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #411 out of 831 companies for Beneish M-Score. This puts Jazz Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Beneish M-Score is -2.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (JAZZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $151.23, compared to a current price of $229.93 — trading 52% above its estimated fair value. The current Beneish M-Score is -2.38. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Jazz Pharmaceuticals (JAZZ), the current Beneish M-Score is -2.38 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of $229.93 is trading 52% above its estimated GF Value™ of $151.23.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for JAZZ:
Beneish M-Score: -2.38
GF Value™: $151.23 vs. price of $229.93 (52% above fair value)
No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for JAZZ
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAZZ has been successfully added to your 
